New Weight Loss Pill Surpasses Oral Ozempic in Clinical Trial

A new once-daily oral weight-loss pill, orforglipron, demonstrated superior weight loss and blood sugar control compared to the leading oral GLP-1 receptor agonist semaglutide in a major clinical trial. The Phase 3 study, published in *The New England Journal of Medicine*, found that participants taking orforglipron lost an average of 18.8% of their body weight over 52 weeks, compared to 15.2% with semaglutide, while also showing greater improvements in glycemic markers for individuals with type 2 diabetes. The results position the tablet as a potential alternative to injectable GLP-1 drugs like Ozempic and Wegovy, which currently dominate the weight-management market.

Orforglipron’s oral formulation eliminates the need for refrigeration and allows flexible dosing without meal restrictions, addressing common barriers to adherence with injectable therapies. Its developers note that the pill’s manufacturing process is more cost-effective, potentially reducing treatment expenses and broadening access in low- and middle-income countries. While safety profiles were comparable between the drugs, further research is underway to assess long-term cardiovascular outcomes and optimal dosing strategies. Regulatory submissions for approval are expected in 2025, pending final data reviews.